• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性切除的淋巴结阳性胃癌患者长期生存的预测因素。

Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection.

作者信息

Kim Dong Yi, Joo Jae Kyoon, Park Young Kyu, Ryu Seong Yeob, Kim Young Jin, Kim Shin Kon

机构信息

Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, 8, Hakdong, Dongku, Gwangju, 501-757, South Korea.

出版信息

Langenbecks Arch Surg. 2007 Mar;392(2):131-4. doi: 10.1007/s00423-006-0114-9. Epub 2006 Nov 7.

DOI:10.1007/s00423-006-0114-9
PMID:17089174
Abstract

BACKGROUND AND AIMS

We analyzed the clinicopathologic features of node-positive gastric carcinoma patients who were long-term survivors (5 years or longer) and evaluated the predictive factors associated with long-term survival.

PATIENTS AND METHODS

Of 554 node-positive gastric carcinoma patients with curative resection, 161 (29.1%) were long-term survivors, and 393 died of the disease before 5 years.

RESULTS

The long-term survivor group had a recurrence rate of 16.1%, while the recurrence rate was 95.4% in the short-term survivor group (P < 0.05). The mean tumor size in the long-term survivors (4.5 cm) was significantly smaller than that in the short-term survivors (5.3 cm; P < 0.001). A depth of invasion greater than T3 was found more frequently in the short-term survivor group (88.1%) than in the long-term survivor group (70.1%; P < 0.001). Using Cox's proportional hazard regression model, the only factor found to be an independent, statistically significant prognostic parameter was tumor size (risk ratio, 0.301; 95% confidence interval, 0.10-0.88; P < 0.05).

CONCLUSION

The tumor size emerged as the only independent, significant factor for the prediction of long-term survival in node-positive gastric carcinoma patients with curative resection.

摘要

背景与目的

我们分析了长期生存(5年或更长时间)的淋巴结阳性胃癌患者的临床病理特征,并评估了与长期生存相关的预测因素。

患者与方法

在554例行根治性切除的淋巴结阳性胃癌患者中,161例(29.1%)为长期生存者,393例在5年内死于该疾病。

结果

长期生存组的复发率为16.1%,而短期生存组的复发率为95.4%(P<0.05)。长期生存者的平均肿瘤大小(4.5cm)显著小于短期生存者(5.3cm;P<0.001)。短期生存组(88.1%)中浸润深度大于T3的情况比长期生存组(70.1%)更常见(P<0.001)。使用Cox比例风险回归模型,发现唯一具有统计学意义的独立预后参数是肿瘤大小(风险比,0.301;95%置信区间,0.10 - 0.88;P<0.05)。

结论

肿瘤大小是预测行根治性切除的淋巴结阳性胃癌患者长期生存的唯一独立显著因素。

相似文献

1
Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection.根治性切除的淋巴结阳性胃癌患者长期生存的预测因素。
Langenbecks Arch Surg. 2007 Mar;392(2):131-4. doi: 10.1007/s00423-006-0114-9. Epub 2006 Nov 7.
2
Multivariate prognostic study on node-positive gastric cancer: is tumor size a prognostic indicator?淋巴结阳性胃癌的多因素预后研究:肿瘤大小是一个预后指标吗?
Hepatogastroenterology. 2012 Mar-Apr;59(114):623-6. doi: 10.5754/hge11455.
3
Predictors of long-term survival in large gastric carcinoma patients.大型胃癌患者长期生存的预测因素
Hepatogastroenterology. 2011 Nov-Dec;58(112):2162-5. doi: 10.5754/hge09129.
4
Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients.与淋巴结阴性的晚期胃癌患者复发和长期生存相关的临床病理因素。
Rev Esp Enferm Dig. 2019 Feb;111(2):111-120. doi: 10.17235/reed.2018.5829/2018.
5
Prognostic predictors of patients with carcinoma of the gastric cardia.贲门癌患者的预后预测因素
Hepatogastroenterology. 2012 May;59(115):930-3. doi: 10.5754/hge09356.
6
Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer.基于结外转移的淋巴结外软组织分期与胃癌患者的预后不良相关。
J Surg Res. 2014 Nov;192(1):90-7. doi: 10.1016/j.jss.2014.05.053. Epub 2014 May 23.
7
Recurrence in early gastric cancer--presence of micrometastasis in lymph node of node negative early gastric cancer patient with recurrence.早期胃癌复发——复发的淋巴结阴性早期胃癌患者淋巴结中微转移的存在情况
Hepatogastroenterology. 2007 Mar;54(74):620-4.
8
Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes.无论检查的淋巴结数量多少,淋巴结比率都是可切除(R0)胃癌患者的独立预后因素。
Am J Clin Oncol. 2013 Aug;36(4):325-30. doi: 10.1097/COC.0b013e318246b4e9.
9
Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer.对于进展期远端胃癌,在标准D2胃切除术中增加肠系膜上静脉淋巴结(14v)清扫后生存率提高。
Surgery. 2014 Mar;155(3):408-16. doi: 10.1016/j.surg.2013.08.019. Epub 2013 Nov 25.
10
Prediction of lymph node metastasis by size of early gastric carcinoma.早期胃癌大小对淋巴结转移的预测
Hepatogastroenterology. 2007 Mar;54(74):602-5.

引用本文的文献

1
Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward.胃癌的新辅助治疗:向前迈出的决定性一步。
Gastrointest Tumors. 2014 Jun;1(2):99-104. doi: 10.1159/000362577. Epub 2014 May 9.
2
Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer.胃癌患者肿瘤大小预后意义的分层分析。
PLoS One. 2013;8(1):e54502. doi: 10.1371/journal.pone.0054502. Epub 2013 Jan 30.
3
Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.

本文引用的文献

1
Predictors of long-term survival in pN3 gastric cancer patients.pN3期胃癌患者长期生存的预测因素
J Surg Oncol. 2004 Oct 1;88(1):9-13. doi: 10.1002/jso.20130.
2
Is tumor size a prognostic indicator for gastric carcinoma?肿瘤大小是胃癌的预后指标吗?
Anticancer Res. 2002 Nov-Dec;22(6B):3673-7.
3
Japanese Classification of Gastric Carcinoma - 2nd English Edition -.日本胃癌分类 - 第二英文版 -
5-氟尿嘧啶为基础的新辅助化疗治疗局部进展期胃/胃食管交界癌的疗效:荟萃分析。
World J Gastroenterol. 2012 Dec 28;18(48):7384-93. doi: 10.3748/wjg.v18.i48.7384.
4
Expression levels of microRNA-192 and -215 in gastric carcinoma.胃腺癌中 microRNA-192 和 -215 的表达水平。
Pathol Oncol Res. 2012 Jul;18(3):585-91. doi: 10.1007/s12253-011-9480-x. Epub 2011 Dec 29.
5
Clinicopathologic characteristics of serosa-positive gastric carcinoma in elderly patients.老年浆膜阳性胃癌的临床病理特征
J Korean Surg Soc. 2011 Jul;81(1):19-24. doi: 10.4174/jkss.2011.81.1.19. Epub 2011 Jul 11.
6
Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?胃癌:今天外科医生、肿瘤学家和内镜医生的位置在哪里?
World J Gastrointest Oncol. 2011 Jan 15;3(1):10-3. doi: 10.4251/wjgo.v3.i1.10.
7
Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.卡铂和紫杉醇序贯氟嘧啶类似物及放疗作为胃癌辅助治疗的安全性和可行性
Case Rep Oncol. 2009 Nov 21;2(3):220-228. doi: 10.1159/000250082.
8
Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.miR-148a 和 miR-152 在胃肠癌中的表达改变及其临床意义。
J Gastrointest Surg. 2010 Jul;14(7):1170-9. doi: 10.1007/s11605-010-1202-2. Epub 2010 Apr 27.
9
Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction.胃癌和胃食管交界癌全身治疗的当前策略
J Cancer Res Clin Oncol. 2009 Jan;135(1):29-38. doi: 10.1007/s00432-008-0425-z. Epub 2008 Jun 4.
Gastric Cancer. 1998 Dec;1(1):10-24. doi: 10.1007/s101209800016.
4
Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer.扩大淋巴结清扫术与淋巴结阴性胃癌的生存获益相关。
J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31. doi: 10.1016/s1091-255x(98)80002-4.
5
Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study.胃癌的相关预后因素:德国胃癌研究十年结果
Ann Surg. 1998 Oct;228(4):449-61. doi: 10.1097/00000658-199810000-00002.
6
Prognostic factors of node-negative gastric carcinoma: univariate and multivariate analyses.淋巴结阴性胃癌的预后因素:单因素和多因素分析。
J Am Coll Surg. 1997 Apr;184(4):373-7.
7
Tumor size as a simple prognostic indicator for gastric carcinoma.肿瘤大小作为胃癌的一个简单预后指标。
Ann Surg Oncol. 1997 Mar;4(2):137-40. doi: 10.1007/BF02303796.
8
Epidemiology of gastric cancer.
Semin Oncol. 1996 Jun;23(3):281-91.
9
Long-term survival after resection for advanced gastric carcinoma.
J Clin Gastroenterol. 1995 Oct;21(3):208-10. doi: 10.1097/00004836-199510000-00008.
10
A clinicopathologic study of gastric carcinoma with reference to age of patients.
J Clin Gastroenterol. 1994 Jun;18(4):287-90. doi: 10.1097/00004836-199406000-00006.